Maxygen hands out pink slips

Maxygen is laying off 25 workers - 16% of its workforce - as it focuses more of its resources on clinical development and away from early-stage research. The Redwood City, CA-based company plans to ask the FDA next year for approval to start trials on two therapies - interferon alpha and GCSF.

- read this report from the San Francisco Business Times for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.